Skip to content

Economics

Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.

Screenshot 2022-07-15 at 11.50.46Plasma & Platelets

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

Prof. Dr. Florian Kron
Managing Director
VITIS Healthcare group

EN DE ES PL RU

Screenshot 2022-07-15 at 11.57.51

Platelets

Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects 

Dr. Konrad Rosskopf
Dept. Transfusion Medicine
University Hospital of Graz, Austria

EN DE ES PL RU

Screenshot 2022-07-15 at 13.04.10Platelets

Strategies to minimise budget impact and increase cost effectiveness of pathogen inactivation

Filip De Groof
Consultant
Cerus BV

EN DE ES PL RU

Screenshot 2022-07-15 at 13.25.12Plasma & Platelets

How to bring bacterial risk control strategies within financial reach

Kathleen Rowe
Sr. Global Health Policy Director
Cerus BV

EN DE ES PL PL

cerus_large_2x

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0